biotricity on the Path to Reaching its Goals
biotricity on the Path to Reaching its Goals
Marina del Rey, CA - December 14, 2016.   In July 2016 SWI released its first research report on biotricity. Since then the company has made significant progress on the path to reaching its goals. Make yourself familiar again by downloading the initial research report below. We will publish an updated SWI research report next week.
  “And just as we’ve seen in … our life where our iPhone, our iPad is converging into other 
areas, I think we’re going to see the same thing in medical device technology …  in consumer 
and pharma in different ways. All of the instruments will be smart instruments by the way that 
they are integrated into the operating room and connected in a number of different ways …”  

Alex Gorsky - CEO - Johnson & Johnson

Changing the Industry via Mobile Solutions

biotricity is a medical technology company committed to improving healthcare by developing mobile remote monitoring solutions that aid chronic disease prevention and management. bio tricity’s premier product is  bio flux, a mobile ECG monitoring system that will be prescribed by physicians to diagnose and remotely monitor cardiac patients. biotricity is expanding medical-grade monitoring into the consumer market via its biolife solution, which empowers users to self-manage chronic conditions. b io tricity has entered into crucial development partnerships with Canada NRC-CNRC, Alberta Health Services and the University of Calgary. Current projects are being funded by the NRCC, including a study to determine if ECG readings have predictive value for use in preventive healthcare.         
Mobile Cardiac Telemetry - An Underserved Market
Rainer Poertner - Chief Analyst
 StockWatchIndex  and SWI Research (SWI) are not registered investment advisers and the information  provided herein or any other SWI publication is not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in its publications or on its web sites. Some of the published information has been provided by the companies covered, generated by publicly available sources, or what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in this publication, any other SWI publication, or its web sites and is not obligated to update and/or correct information. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. SWI expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. SWI has been engaged by biotricity top advertise this report and will be compensated in stock options at fair market value for the publication of the information herein. The included information is subject to change without notice. Please visit!legal-ease/lmvw1   for a full text of our Disclaimer, Privacy policy and Terms of Use.